OPCO Inc.

Private Company, Headquarters Location
PO Box 101, Latrobe, PA 15650, United States
(724)537-9300, (724)537-9349 fax,

Primary SIC: Plastics Materials Synthetic Resins, Primary NAICS: Plastics Material and Resin Manufacturing
Description: Manufacturing: Manufactures polystyrene resins; wholesales plastic materials

View this company profile - Now for a Limited Time, try Goliath Company Profiles
Free for 3 Days!

OPCO Inc., News and Information

Addus HomeCare Corporation Prices Initial Public Offering.
Investment Weekly News; 11/14/2009; 746 words; ...joint book-running managers, and Stephens Inc. acted as co-manager. The shares of...800) 792-2473 or Oppenheimer & Co. Inc., Attention: Syndicate Prospectus Department...8563, or via email at EquityProspectus@opco.com. A registration statement relating...

Universal City Florida Holding Co. I and II Announce Tender Offer and Consent Solicitation for 8 3/8% Senior Notes Due 2010 and Floating Rate Senior Notes Due 2010.
Leisure & Travel Week; 11/14/2009; 1580 words; ...3/4% senior notes (the "Opco Notes") issued by Universal...Partners, Ltd. and UCDP Finance, Inc. representing a majority of the principal amount of such Opco Notes outstanding on the Consent...Documents. J.P. Morgan Securities Inc., Banc of America Securities...

BioReference Laboratories, Inc to Speak at the Oppenheimer 20th Annual Health Care Conference.(Conference news)
Computer Weekly News; 11/12/2009; 654 words; BioReference Laboratories, Inc (NASDAQ:"BRLI") announced...veracast.com/webcasts/opco/healthcare09/51108419.cfm...About BioReference Laboratories, Inc. BRLI is the third largest full...BioReference Laboratories, Inc, BioReference Laboratories...

DJO Incorporated Announces Financial Results for Third Quarter 2009.(Financial report)
Biotech Week; 11/11/2009; 2008 words; ...DJOFL"), for the third quarter of 2009, ended September 26, 2009. ReAble Therapeutics, Inc. ("ReAble") acquired DJO Incorporated ("DJO Opco") in a transaction completed on November 20, 2007 (the "DJO Merger"). Following completion...

Curis to Present at the Oppenheimer 20th Annual Healthcare Conference.(Conference news)
Cancer Weekly; 11/10/2009; 958 words; Curis, Inc. (NASDAQ: CRIS), a drug...York City (see also Curis, Inc.). Dan Passeri, Curis' President...veracast.com/webcasts/opco/healthcare09/14113292.cfm...curis.com. About Curis, Inc. Curis is a drug development...

Why Purchase This Company Profile?

  • Sales prospecting
  • Competitive analysis
  • Vendor & supplier evaluation
  • Customer evaluation and analysis
  • Strategic planning

Need More Information?

Start a new search

Tell Us What You Think

Take our short survey to tell us what would make Goliath more valuable to you.

Add Your Company Information to Goliath
If your company does not appear in Goliath, click here to add it.

Update Your Company Information
If your company information has changed or is not correct,
click here to let us know.